JD Health (SEHK:6618): Valuation Insights Following New Partnership to Boost Chronic Disease Services and Online Reach

Simply Wall St.11-25

JD Health International (SEHK:6618) has partnered with ClouDr Group Limited to expand its online sales presence and improve chronic disease management services. The collaboration aims to combine the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586477557?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176","is_english":true,"pubTime":"2025-11-25 21:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586477557","market":"nz","top_or_hot":-1,"title":"JD Health (SEHK:6618): Valuation Insights Following New Partnership to Boost Chronic Disease Services and Online Reach","media":"Simply Wall St.","content":"<div>\n<p>JD Health International (SEHK:6618) has partnered with ClouDr Group Limited to expand its online sales presence and improve chronic disease management services. The collaboration aims to combine the ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-sehk6618-valuation-insights-following-new-partners\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health (SEHK:6618): Valuation Insights Following New Partnership to Boost Chronic Disease Services and Online Reach</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health (SEHK:6618): Valuation Insights Following New Partnership to Boost Chronic Disease Services and Online Reach\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-25 21:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-sehk6618-valuation-insights-following-new-partners><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JD Health International (SEHK:6618) has partnered with ClouDr Group Limited to expand its online sales presence and improve chronic disease management services. The collaboration aims to combine the ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-sehk6618-valuation-insights-following-new-partners\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4122","symbol_name":"互联网与直销零售","start_time":0,"source_url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-sehk6618-valuation-insights-following-new-partners","article_id":"2586477557","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/4422000-choice1-main-header/1585186589176"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/consumer-retailing/hkg-6618/jd-health-international-shares/news/jd-health-sehk6618-valuation-insights-following-new-partners","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2586477557","pubTimestamp":1764076854,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"JD Health International (SEHK:6618) has partnered with ClouDr Group Limited to expand its online sales presence and improve chronic disease management services. The collaboration aims to combine the scale of JD Health with the specialized medical expertise of ClouDr.\nSee our latest analysis for JD Health International.\nJD Health International’s latest partnership comes on the heels of a stellar run, with its share price soaring 135.61% year-to-date. While there has been a modest dip over the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","BK4122":"互联网与直销零售","BK1583":"高瓴概念","BK4585":"ETF&股票定投概念","BK4558":"双十一","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4505":"高瓴资本持仓","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","BK4504":"桥水持仓","IE0008368742.USD":"首域中国增长基金I Acc","BK4220":"综合零售","BK1589":"北水核心资产","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","BK4614":"Manus概念股","BK4579":"人工智能","BK1142":"互联网与直销零售","GMV.AU":"G Medical Innovations","LU0051755006.USD":"摩根大通中国A (dist)","LU1688375341.USD":"贝莱德中国灵活股票基金","SG9999002463.SGD":"LionGlobal China Growth SGD","BK4588":"碎股","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK4551":"寇图资本持仓","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK4509":"腾讯概念","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","BK4524":"宅经济概念","BK1615":"港股-互联网","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","BK1571":"互联网医疗","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4531":"中概回港概念","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","06618":"京东健康","BK1515":"抗疫概念","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC","BK4526":"热门中概股","BK1247":"药品零售","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","BK1591":"就地过年概念","BK4503":"景林资产持仓"},"translate_title":"京东健康（SEHK：6618）：新合作伙伴关系推动慢性病服务和在线覆盖后的估值见解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":0.6,"GMV.AU":1,"06618":0.9},"content_text":"JD Health International (SEHK:6618) has partnered with ClouDr Group Limited to expand its online sales presence and improve chronic disease management services. The collaboration aims to combine the scale of JD Health with the specialized medical expertise of ClouDr. See our latest analysis for JD Health International. JD Health International’s latest partnership comes on the heels of a stellar run, with its share price soaring 135.61% year-to-date. While there has been a modest dip over the past week, the stock’s impressive 1-year total return of 130.37% points to strong momentum building this year, even though the 3-year total shareholder return remains slightly negative. If you’re watching healthcare disruptors making strategic moves, now is a great time to discover other innovators with potential. See the full list here: See the full list for free. With recent gains and strong revenue growth, is JD Health International still trading below its true value, or is future growth already reflected in share prices? Is this a genuine buying opportunity, or has the market already priced in all the upside? AdvertisementMost Popular Narrative: 11.5% Undervalued JD Health International’s current fair value estimate from the most popular narrative stands at HK$70.25, which is about 13% above the last close price. This disconnect suggests that the market may not be fully reflecting the company’s projected growth and margin story. Let's take a closer look at what’s fueling this view.  Rapid acceleration in AI integration across medical consultations, diagnostics, and service delivery is driving higher operational efficiency, elevated user satisfaction, and improved conversion rates. This trend supports upward momentum in both revenue and net margins. The expanding omnichannel supply chain, including B2C, O2O, and offline pharmacy stores, boosts accessibility of pharmaceutical products and healthcare services nationwide, fueling further growth in active user numbers, order volumes, and gross merchandise value (GMV). This in turn enhances revenue and potential scale-driven margin improvements.  Read the complete narrative. Curious which trends are powering this bullish narrative? There’s a quantitative “growth formula” hiding behind those revenue projections and profit margin ambitions. Wondering which innovative moves are expected to justify the future multiple? Dig deeper to see the surprising assumptions driving this fair value. Result: Fair Value of $70.25 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, intensifying competition from leading digital health rivals and unexpected regulatory shifts could present significant headwinds to JD Health International’s bullish outlook. Find out about the key risks to this JD Health International narrative. Another View: Multiples Paint a Riskier Picture Our SWS DCF model suggests JD Health International is actually trading above its calculated fair value of HK$43.61. This puts the current price at a premium, which could indicate possible overvaluation if future growth expectations are overly optimistic. Could analyst enthusiasm be running ahead of fundamentals? Look into how the SWS DCF model arrives at its fair value. 6618 Discounted Cash Flow as at Nov 2025 Build Your Own JD Health International Narrative If you want to dig deeper, the choice is yours. Take a hands-on approach and build your own view in just a few minutes. Do it your way A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding JD Health International. Looking for More Investment Ideas? Smart investing means always keeping your radar up for fresh opportunities. Don’t let today’s gains stop you from finding tomorrow’s potential winners. Challenge yourself to look beyond the obvious and stay ahead of the market crowd.  Unlock serious cash flow potential by targeting undervalued companies. Check out these 921 undervalued stocks based on cash flows to spot those trading below their intrinsic worth before the crowd catches on. Power up your passive income strategy by searching for businesses that offer market-beating yields. Start with these 14 dividend stocks with yields > 3% and uncover options with strong dividends and stability. Lead the charge in artificial intelligence by considering these 26 AI penny stocks that are shaping industries and redefining what’s possible in tech-driven growth.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586477557","isCrawlerRequest":true}